WINTER SPRINGS, Fla., Dec. 12, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only ...
Iradimed Corporation announced that it has received FDA 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System, making it the only supplier of non-magnetic MRI-compatible ...
IRadimed Corporation offers steady revenue growth with 14 consecutive quarters of record revenue and a small dividend, despite recent stock price decline. IRMD's unique MRI-compatible IV infusion pump ...
Roth MKM has resumed coverage of iRadimed (NASDAQ:IRMD) with a buy rating citing the company's position as the sole provider of MRI-compatible IV pumps. The firm has a $65 price target (~59% upside ...
Total Revenue-- $21.2 million for the third quarter of 2025, up 16%, driven by MRI compatible IV infusion pump and monitoring system growth. Gross Profit and Margin-- $16.4 million at 78% margin for ...
Immediately resumes shipments of patient vital signs monitoring systems into all markets requiring CE Mark WINTER SPRINGS, Fla., Dec. 12, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback